Follow us on Twitter
twitter icon@FreshPatents


Diabetes patents

      

This page is updated frequently with new Diabetes-related patent applications.

SALE: 520+ Diabetes-related patent PDFs



 Electronic phenotyping technique for diagnosing chronic kidney disease patent thumbnailElectronic phenotyping technique for diagnosing chronic kidney disease
An example method of diagnosing chronic kidney disease (ckd) includes obtaining an electronic medical record for a patient having medical data. The medical data includes an indication if the patient had been previously diagnosed with ckd, an indication if the patient had previously undergone a kidney transplant, an indication if the patient had previously undergone a renal dialysis procedure, an indication if the patient had previously been diagnosed with another type of kidney disease, one or more glomerular filtration rate (gfr) measurements associated with the patient, an indication if the patient has type 2 diabetes, and/or an indication if the patient has hypertension.
Icahn School Of Medicine At Mount Sinai


 Insulinotropic peptide derivative with modified n-terminal charge patent thumbnailInsulinotropic peptide derivative with modified n-terminal charge
The present invention relates to an insulinotropic peptide derivative with a modified n-terminal charge and a pharmaceutical composition including the same. Specifically, the insulinotropic peptide derivative is characterized in that the n-terminal positive charge of the insulinotropic peptide is modified to a neutral or net negative charge at neutral ph.
Hanmi Pharm. Co., Ltd.


 Chemical compounds and use thereof for improving muscular quality patent thumbnailChemical compounds and use thereof for improving muscular quality
Chemical compounds and the therapeutic use thereof, in particular for improving muscular quality in mammals. More particularly, a method of improving muscular quality in sarcopenic mammals and treating and/or preventing sarcopenia using the chemical compounds and, in particular, sarcopenic obesity and the associated complications and/or pathologies thereof, such as loss of strength, muscle mass, performance and of physical and movement capacity.
Universite Paris 6 Pierre Et Marie Curie


 N-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase patent thumbnailN-(5-((aryl or heteroaryl)methyloxy)pentyl)-substituted iminosugars as inhibitors of glucosylceramide synthase
Deoxynojirimycin and deoxygalactonojirimycin derivatives according to the present invention are n-alkylated d-galacto, d-gluco- or l-ido-deoxynojirimycin with a linear methyloxypentyl group bearing various sidegroups and a non-fused bicyclic aromatic group (“x”) on the methyloxy-carbon. These compounds display an increased inhibitory potency towards gcs, and/or an increased inhibitory potency towards gba2, and/or a decreased inhibitory potency towards gba1, relative to known deoxynojirimycin derivatives of the same (d-gluco, l-ido or d-galacto) configuration.
Universiteit Leiden


 Device for attachment to a portable liquid injection device patent thumbnailDevice for attachment to a portable liquid injection device
The invention refers to a device for attachment to a portable liquid injection device, wherein said device is designed to enclose the drug reservoir of the injection device completely. Further, said device has at least two flat conductive electrodes enabling an electrical field to be applied across the entire volume of the drug reservoir of the injection device.
Valtronic Technologies (holding) Sa


 Method of preventing and treating retinal microvasculature inflammation using c-met signaling pathway inhibition patent thumbnailMethod of preventing and treating retinal microvasculature inflammation using c-met signaling pathway inhibition
The present invention provides methods for preventing retinal microvasculature inflammation in patients with diabetes who are highly susceptible to developing diabetic retinopathy and/or diabetic macular edema. The methods comprise inhibiting c-met signaling pathway by administering a c-met inhibitor alone or in combination with anti-vegf or steroid medications to diabetic patients.

 Nutritional support  health issues patent thumbnailNutritional support health issues
A method of improving the outcome or recovery for depression, diabetes, cardiovascular disease, alzheimers progression, or breast cancer. This method consists of administering a food which includes transfer factor, lactic acid generating bacteria, and/or glucans in appropriate combinations and dosage levels.
Cortcontrol


 Phospholipid-containing marine extracts for treatment of cardiovascular diseases patent thumbnailPhospholipid-containing marine extracts for treatment of cardiovascular diseases
The present invention relates to a method of treatment and/or prevention of cardiovascular disease, rheumatoid arthritis, skin cancer, premenstrual syndrome, diabetes and transdermal transport enhancement. The method comprises the administration of a therapeutically effective amount of krill and/or marine oil to a patient.
Neptune Technologies & Bioressources, Inc.


 Aromatic farnesyl compound and application thereof patent thumbnailAromatic farnesyl compound and application thereof
Aromatic farnesyl compound and application of a pharmaceutical salt thereof as an inhibitor of α-glucosidase, dipeptidyl peptidase-4, aldose reductase, protein tyrosine phosphatase-1b or hmg-coa reductase, or use thereof in preparing medicine and functional healthcare products having a liver protective function and/or for treating and/or preventing type ii diabetes, diabetic retinopathy, diabetic foot disease, and hyperlipidemia.. .
Institute Of Microbiology, Chinese Academy Of Sciences


 Specialized flour for nutrition meals for diabetes and preparation method and use thereof patent thumbnailSpecialized flour for nutrition meals for diabetes and preparation method and use thereof
Disclosed are specialized flour for nutrition meals for diabetes and a preparation method and use thereof. The flour is based on cereal meal as a basic material and is added to a defatted soybean vegetable protein powder and a soybean tissue isolated dietary fiber power, wherein in the dry flour base, the content of protein is 20-26 weight %, the content of the dietary fiber is 4-10 weight %, the content of carbohydrate is no more than 65 weight %, and the content of fat is no more than 4% of the weight.

System and decision support using lifestyle factors

Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions.
Dexcom, Inc.

System and decision support using lifestyle factors

Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions.
Dexcom, Inc.

Composition and using mir-302 precursors as drugs for treating alzheimer's diseases

This invention generally relates to a composition and method of using recombinant micrornas (mirna) and their hairpin-like precursors (pre-mirna) as therapeutic drugs for treating alzheimer's diseases (ad). More specifically, the present invention relates to the use of man-made mirna mir-302 precursors (pre-mir-302) for ad therapy in humans.
Mello Biotechnology, Inc.

Compositions and methods for measuring nmu and for treatment using anti-nmu agents

The inventors have produced two high specificity and high affinity monoclonal antibodies that bind to human neuromedin u (nmu). Methods and compositions are provided for treating an individual in need thereof (e.g., an individual who is obese and/or has diabetes) by administering an anti-nmu/nmur agent (e.g., an anti-nmu antibody).
The Board Of Trustees Of The Leland Stanford Junior University

Humanized antibodies specific for hsp65-derived peptide-6, methods and uses thereof

The present invention relates to humanized antibodies that specifically bind a polypeptide comprising peptide-6 as denoted by seq id no. 15, that is an hsp65 derived peptide.
Protab Ltd.

Novel 3-amino-pyrrolo[3,4-c]pyrazole-5(1h, 4h,6h) carbaldehyde derivatives

Wherein a, b, r1, r2, r3, r4, r5, r6, r7, r8, r9 and r10 are as defined above. The invention further relates to pharmaceutical compositions comprising the compounds and pharmaceutically acceptable salts and to methods of treating diabetes mellitus and its complications, cancer, ischemia, inflammation, central nervous system disorders, cardiovascular disease, alzheimer's disease and dermatological disase pression, virus diseases, inflammatory disorders, or diseases in which the liver is a target organ..

Amlexanox analogs

Provided herein are amlexanox analogs and methods for the treatment and/or prevention of diabetes, impaired insulin signaling, obesity, or other related diseases and conditions therewith.. .
The Regents Of The University Of Michigan

[7,6]-fused bicyclic antidiabetic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Pyrrolidine gpr40 modulators for the treatment of diseases such as diabetes

The present invention provides compounds of formula (i) or a stereoisomer, a tautomer, a pharmaceutically acceptable salt, or a solvate thereof, wherein all of the variables are as defined herein. These compounds are gpr40 g protein-coupled receptor modulators which may be used as medicaments..
Bristol-meyers Squibb Company

Antidiabetic bicyclic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Antidiabetic bicyclic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Substituted 1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl)acetic acid derivatives useful in the treatment of autoimmune and inflammatory disorders

Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of s1p1 receptor-associated disorders, for example, psoriasis, rheumatoid arthritis, crohn's disease, transplant rejection, multiple sclerosis, systemic lupus erythematosus, ulcerative colitis, type i diabetes, acne, microbial infections or diseases and viral infections or diseases.. .

Swallowable capsule and stimulating incretin production within the intestinal tract

Embodiments of the invention provide apparatus and methods for stimulating l cells in the intestinal tract to produce incretins for the treatment of conditions including diabetes and obesity. Many embodiments provide a method and apparatus for the treatment of diabetes by electrically stimulating l-cells to secrete incretins to stimulate or otherwise modulate the production of insulin.
Incube Labs, Llc

Dry powder inhaler

A dry powder inhaler including replaceable cartridges containing a dry powder for local or systemic delivery through the pulmonary tract and lungs is disclosed. The inhalers are used with inhalable dry powders, including medicament formulations comprising active agents for local or systemic delivery and for the treatment of diseases such as, pulmonary hypertension, cardiovascular disease, anaphylaxis, diabetes, obesity, cancer, and other diseases, or symptoms associated with these and other diseases, such as nausea, vomiting, pain and inflammation..
Mannkind Corporation

System and decision support using lifestyle factors

Systems and methods are provided relating to open loop decision-making for management of diabetes. People with diabetes face many problems in controlling their glucose because of the complex interactions between food, insulin, exercise, stress, activity, and other physiological and environmental conditions.
Dexcom, Inc.

Functionalized exendin-4 derivatives

The present invention relates to exendin-4 derivatives and their medical use, for example in the treatment of disorders of the metabolic syndrome, including diabetes and obesity, as well as reduction of excess food intake.. .
Sanofi

Use of dehydroeburicoic acid from antrodia camphorata in the treatment or prevention of diabetes and hyperlipidemia

The present invention provides a method for treating type 1 diabetes, hyperlipidemia or hepatic lipid accumulation by using dehydroeburicoic acid, as well as a method for decreasing levels of blood glucose, plasma total cholesterol, and triglyceride, and increasing insulin levels; and a method for decreasing hepatic balloon degeneration; and increasing expression levels of membrane glut4 and phospho-akt in myotubes; and enhancing expression levels of membrane glucose transporter 4 (glut4) in skeletal muscle, and phospho-ampk in both skeletal muscle and liver tissue using dehydroeburicoic acid.. .

Phenoxy acetic acids and phenyl propionic acids as ppar delta agonists

Phenoxy acetic acids and phenyl propionic acids and their use in treating type i diabetes, type ii diabetes, impaired glucose tolerance, insulin resistance, or obesity are provided herein. The present compounds are activators of pparδ and may be useful for treating conditions mediated by the same..
Vtv Therapeutics Llc

Aldose reductase inhibitors and uses thereof

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like..
The Trustees Of Columbia University In The City Of New York

Aldose reductase inhibitors and uses thereof

The present invention relates to novel compounds and pharmaceutical compositions thereof, and methods for promoting healthy aging of skin, the treatment of skin disorders, the treatment of cardiovascular disorders, the treatment of renal disorders, the treatment of angiogenesis disorders, such as cancer, treatment of tissue damage, such as non-cardiac tissue damage, the treatment of evolving myocardial infarction, and the treatment of various other disorders, such as complications arising from diabetes with the compounds and compositions of the invention. Other disorders can include, but are not limited to, atherosclerosis, coronary artery disease, diabetic nephropathy, diabetic neuropathy, diabetic retinopathy, infections of the skin, peripheral vascular disease, stroke, and the like..
The Trustees Of Columbia University In The City Of New York

Compositions for treating or preventing obesity and insulin resistance disorders

Provided herein are methods and compositions for modulating the activity or level of a sirtuin, thereby treating or preventing obesity or an insulin resistance disorder, such as diabetes in a subject. Exemplary methods comprise contacting a cell with a sirtuin activating compound or an inhibitory compound to thereby increase or decrease fat accumulation, respectively..
The General Hospital Corporation D/b/a Massachusetts General Hospital

Methods of treating diabetes by administering a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor

Use of a glucagon receptor antagonist in combination with a cholesterol absorption inhibitor for the treatment of diabetes and related conditions is disclosed.. .
Merch Sharp & Dohme Corp.

Glucagon antagonists

Provided herein are compounds, including enantiomerically pure forms thereof, and pharmaceutically acceptable salts or co-crystals and prodrugs thereof which have glucagon receptor antagonist or inverse agonist activity. Further, provided herein are pharmaceutical compositions comprising the same as well as methods of treating, preventing, delaying the time to onset or reducing the risk for the development or progression of a disease or condition for which one or more glucagon receptor antagonist is indicated, including type i and ii diabetes, insulin resistance and hyperglycemia.
Ligand Pharmaceuticals, Inc.

Screening and monitoring the progression of type 2 diabetes by the molecular identification of human gut flora using fta as a faecal collection device

Disclosed is a method for detecting and quantifying gut flora derived from human faeces, comprising acquiring a solid support containing human faeces; optionally amplifying nucleic acid from the human faeces; and detecting and quantifying the presence of gut flora of interest. Also disclsoed is a method for assessing whether a person has type-2 diabetes as well as a kit for detecting and quantifying gut flora from human faeces, comprising a solid support for collecting human faeces; and primer pairs for amplifying 16s rrna sequence from bacteria of interest..
Ge Healthcare Uk Limited

High-purity galactooligosaccharide compositions, preparations, and applications thereof

Provided is a method of preparing a high-purity galactooligosaccharide composition by fermentation of a low-purity galactooligosaccharide mixture with a yeast strain, kluyveromyces lactis atcc 8585. The high-purity galactooligosaccharide composition includes at least 99% of galactooligosaccharides selected from the group consisting of galactotriose, galactotetrose, galactooligosaccharides with five or more sugar units, and combinations thereof and lower than 1% of monosaccharides and disaccharides.
King-prebiotics Biotechnology (tw) Co., Ltd.

[5,6]-fused bicyclic antidiabetic compounds

Novel compounds of the structural formula (i), and the pharmaceutically acceptable salts thereof, are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40. The compounds of the present invention may be useful in the treatment of type 2 diabetes mellitus, and of conditions that are often associated with this disease, including obesity and lipid disorders, such as mixed or diabetic dyslipidemia, hyperlipidemia, hypercholesterolemia, and hypertriglyceridemia..
Merck Sharp & Dohme Corp.

Deutero-phenformin derivatives

The present disclosure is directed to novel phenformin derivatives, and their pharmaceutically acceptable salts, solvates, or stereoisomers thereof. This disclosure also provides compositions and the use of such compositions in method of treating cancer, diabetes, or polycystic ovarian syndrome..
Enlibrium Inc

A peptide therapy to counteract insulin resistance and type 2 diabetes

Compositions comprising an antagonist of pancreastatin are provided. The beneficial use of the compositions for treating insulin resistance, diabetes, especially type ii diabetes, inflammation, obesity, non-alcoholic fatty liver disease, atherosclerosis and cardiovascular diseases is described as well..
Indian Institute Of Technology Madras

Therapeutic treatment for metabolic syndrome, type 2 diabetes, obesity, or prediabetes

In another aspect, the present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject. The present invention is also directed to pharmaceutical compositions that include the above compounds and a pharmaceutically acceptable carrier..

Socs1-derived peptide for use in chronic complications of diabetes

The present invention relates to a socs1-derived peptide for use in chronic complications of diabetes, particularly ocular, renal, nerve and vascular complications, as well as compositions containing same and isolated polynucleotides encoding same. The present invention also relates to the socs1-derived peptide for topical use in the treatment and/or prevention of neurodegenerative diseases of the retina, particularly in the early stages of diabetic retinopathy and other diseases of the retina in which neurodegeneration plays an essential role..
Universidad Autónoma De Madrid

Composition for treating obesity and diabetes and for increasing muscle mass and improving capacity for exercise, comprising extracts of piper retrofractum vahl. fruits as active ingredients

The present invention relates to a food composition, and to a pharmaceutical composition, which exhibit anti-obesity effects by means of a thermogenesis produced by an activity of a ucp of fat cells, which exhibit anti-diabetes effects by means of an improved insulin resistance, increase muscle mass, and improve capacity for exercise. More particularly, the present invention relates to a novel use of a composition containing extracts of piper retrofractum, and to the food composition or pharmaceutical composition which exhibit anti-obesity effects by means of decreased body weight and body fat, exhibit anti-diabetes effects by means of ameliorated insulin resistance through the reduction of blood glucose and blood insulin, increase muscle mass by increasing an energy source being supplied to the muscles, and improve the capacity for exercise including increased endurance..
Industry-academic Cooperation Foundation, Yonsei University

A combination of kynurenine and antigen presenting cells (apc) as therapeutics and methods for their use in immune modulation

This invention provides combinations of kynurenine and antigen presenting cells (apc) for modulating immune tolerance, wherein the combinations may be used to modulate an autoimmune response, which may be of use in the treatment of type 1 diabetes (t1d) or alopecia areata (aa). Uses of kynurenine and antigen presenting cells (apc) as an immune modulator for the treatment of t1d or aa are also provided..
The University Of British Columbia

Substituted aromatic compounds and pharmaceutical compositions for the prevention and treatment of diabetes

The present invention concerns the use of compounds for preventing and/or treating diabetes, for modulating glucose, insulin, and/or triglyceride levels; for reducing blood glucose level; for maintaining or increasing insulin level; for increasing insulin secretion; increasing insulin sensitivity; or decreasing insulin resistance in a subject. These novel uses have been found for compounds represented by formula i and pharmaceutically acceptable salts.
Prometic Pharma Smt Limited

Biguanide compositions and methods of treating metabolic disorders

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

Biochemical markers for use in determining risk of diabetes

A method for predicting risk of gestational diabetes mellitus (gdm) in a pregnant individual includes measuring one or more biochemical markers in a blood sample obtained from the pregnant individual to determine one or more biomarker levels, where the one or more measured biochemical markers includes at least one of amylin, 17β-estradiol, and lipocalin-2, identifying, for each of the one or more measured biochemical markers, a difference between the measured biomarker level and a corresponding predetermined control level, and, responsive to the identifying, determining a prediction corresponding to a relative risk of the pregnant individual having or developing gdm.. .
Wallac Oy

Goodpasture antigen binding protein detection and inhibition and its use in diabetes

Disclosed herein are methods for treating type 2 diabetes, limiting development of type 2 diabetes, and treating a pre-diabetic state by administering to a subject in need thereof a gpbp inhibitor. Also disclosed herein are methods for diagnosing a pre-diabetic state and for diagnosing a propensity to develop type 2 diabetes by determining an amount of gpbp in a sample from a subject and comparing to control..
Fibrostatin, S.l.

Method of designing a peptide and/or peptide derivative for modulating gamma-c-cytokine activity

The γc-family cytokines, interleukin-2 (il-2), interleukin-4 (il-4), interleukin-7 (il-7), interleukin-9 (il-9), interleukin-15 (il-15), and interleukin-21 (il-21), are associated with important human diseases, such as leukemia, autoimmune diseases, collagen diseases, diabetes mellitus, skin diseases, degenerative neuronal diseases and graft-versus-host disease (gvhd). Thus, inhibitors of γc-cytokine activity are valuable therapeutic and cosmetic agents as well as research tools.
Bioniz, Llc

Preparation and use of crystalline beta-d-nicotinamide riboside

Provided herein are crystalline beta-d-nicotinamide riboside chloride compositions and methods of preparation and use thereof. Also provided are related pharmaceutical compositions and methods of use thereof.
Glaxosmithkline Intellectual Property (no.2) Limited

Adjusting insulin delivery rates

A method may include delivering insulin, using an insulin pump and a controller, over a first diurnal time period based on a baseline basal insulin rate stored in memory. The controller may receive blood glucose data to control delivery of insulin via the insulin pump in amounts variable from the baseline basal insulin rate to control blood glucose levels for a person with diabetes (pwd).
Bigfoot Biomedical, Inc.

Diabetes management system

A variety of location-based and/or proximity-based features related to diabetes management systems can be used to improve maintenance compliance and/or to provide important information to pwd designated assistance entities (e.g., family, friends, givers, hcps, emergency medicine providers) under certain conditions. In some cases, a user's location can be tracked or determined to trigger and/or time alerts about upcoming maintenance tasks in a way that will increase the likelihood that the pwd will immediately perform the designated maintenance task.
Bigfoot Biomedical, Inc.

Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof

Compositions and preparation method thereof, said compositions comprise an extract from a mixture comprising cyclocarya paliurus leaves and one or more herbs selected from the group consisting of mori cortex, dendrobii caulis and citri reticulatae pericarpium, said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia.. .
Infinitus (china) Company Ltd

Small molecule inhibitors of stat3 with anti-tumor activity

The present invention concerns compounds, compositions containing these compounds, and methods of using these compounds and compositions as inhibitors of stat3 signaling, stat3 dimerization, stat3-dna binding, stat5-dna binding, and/or aberrant cell growth in vitro or in vivo, e.g., as anti-cancer agents for treatment of cancer, such as breast cancer. The compounds of the invention include, but are not limited to, nsc 74859 (s3i-201), nsc 42067, nsc 59263, nsc 75912, nsc 11421, nsc 91529, nsc 263435, and pharmaceutically acceptable salts and analogs of the foregoing.
University Of Central Florida Research Foundation.

Biguanide compositions and methods of treating metabolic disorders

Provided herein are methods for treating certain conditions, including diabetes, obesity, and other metabolic diseases, disorders or conditions by administrating a composition comprising a biguanide or related heterocyclic compound, e.g., metformin. Also provided herein are biguanide or related heterocyclic compound compositions, and methods for the preparation thereof for use in the methods of the present invention.
Elcelyx Therapeutics, Inc.

User interface for diabetes management system

A diabetes management system including a pump for dispensing a medicant and a control device for controlling the pump includes a user interface for controlling functions of the pump and providing information related to operation of the pump and other information. The user interface can display blood glucose information and insulin dosing data such that a user can appropriately act on the information and/or gain confidence that the diabetes management system is operating appropriately to manage the disease.
Bigfoot Biomedical, Inc.

Methods of treating diabetes and compositions capable of same

A composition of matter is disclosed which comprises isolated oligomers of human islet amyloid polypeptide (iapp). Antibodies recognizing same are also disclosed.
Ramot At Tel-aviv University Ltd.

Agonists of the apelin receptor and methods of use thereof

Provided herein are small molecule agonists of the apelin receptor for the treatment of disease. The compounds disclosed herein are useful for the treatment of a range of cardiovascular, renal and metabolic conditions.
Sanford-burnham Medical Research Institute

Ultrashort peptides as exogenous second harmonic probes for bioimaging applications

Various aspects of the present invention relate to a peptide based biomaterial for visualization by shg microscopy. In particular the invention relates to the use of short peptides as a non-linear optical (nlo) material for second harmonic generation (shg) microscopy.
Agency For Science, Technology And Research

Composition for treating diabetes mellitus comprising insulin and a glp-1/ glucagon dual agonist

A composition for preventing or treating diabetes mellitus includes insulin and a glp-1/glucagon dual agonist. The composition can inhibit the weight gain and reduce the danger of hypoglycemia due to the administration of insulin, lower the administration dose and greatly improve the compliance of drugs through a combined administration of a long-acting insulin conjugate and a long-acting glp-1/glucagon dual agonist conjugate.
Hanmi Pharm. Co., Ltd.

Enhancement of glucose-stimulated insulin secretion by cells through induction of cellular senescence

Methods for increasing glucose induced insulin secretion in an insulin secreting cell by inducing senescence in the cell are provided. Further, methods for treating diabetes, by providing cells with increased glucose induced insulin secretion to a subject, as well as a population of modified insulin secreting cells are provided..
Yissum Research Development Company Of The Hebrew University Of Jerusalem Ltd.

Compositions and methods of treating diabetic retinopathy

A method of treating diabetic retinopathy in a subject in need thereof includes administering to the subject a therapeutically effective amount of one or more agents that act as a trap of reactive aldehydes and/or inhibit diabetes-induced superoxide generation and capillary degeneration regulated by gpcr signaling pathways.. .
Case Western Reserve University

Tgr5 agonist complexes for treating diabetes and cancer

Provided herein are complexes of metformin or metformin analogues and a tgr5 ligand that are useful in treating diseases including diabetes, cardiovascular disease, and cancer.. .
City Of Hope

Heterocyclic gsk-3 allosteric modulators

The present invention relates to heterocyclic substituted quinoline derivatives as allosteric inhibitors of the glycogen synthase kinase-3 (gsk-3) enzyme. Therefore, these compounds are useful for the manufacturing of a medicament designed for the treatment and/or prevention of diseases wherein gsk-3 is involved, such as neurodegenerative diseases, inflammatory diseases, cancer, diabetes, and to promote various regenerative processes..
Consejo Superior De Investigaciones Cientificas (csic)

Ex vivo browning of adipose tissue therapy for reversal of obesity and type ii diabetes

Provided are methods, apparatus, pharmaceutical compositions, and kits for treatment of a metabolic condition, including obesity and type 2 diabetes, by administration to a subject of a therapeutically effective amount of a cell or tissue preparation such as brown adipose microtissues or brown adipose tissue directly converted from white adipose tissue. Modified approaches to creating brown adipose tissue involve differentiation of explanted white adipose tissue and direct browning of white adipose tissue in a bioreactor rather than isolation and expansion of adipose stems cells or endothelial cells and formation and differentiation of 3d cell aggregates..
The Trustees Of Columbia University In The City Of New York

Compositions for selective reduction of circulating bioactive soluble tnf and methods for treating tnf-mediated disease

An isolated or synthetic antibody or ligand is provided that specifically binds to an epitope of a dissociated monomer of human tnf. Such binding disrupts assembly of the monomer into bioactive trimeric human stnf.
Thymon, Llc

Alpha1 -antitrypsin compositions and methods of treating autoimmune diseases

The specification provides compositions comprising chimeric proteins comprising aat conjugated to an fc region of an immunoglobulin. Methods for treating autoimmune disease, e.g., diabetes, e.g., type 1 and type 2 diabetes, are also provided..
Beth Israel Deaconess Medical Center, Inc.

Novel glucagon analogues

The present invention relates to novel peptide compounds which have a protracted profile of action and improved solubility and stability, to the use of the compounds in therapy, to methods of treatment comprising administration of the compounds to patients in need thereof, and to the use of the compounds in the manufacture of medicaments. The compounds of the invention are of particular interest in relation to the treatment of hyperglycemia, diabetes and obesity, as well as a variety of diseases or conditions associated with hyperglycemia, diabetes and obesity..
Novo Nordisk A/s

Pyridine derivative

Provided is a pyridine derivative represented by formula (i), a prodrug thereof, a pharmaceutically acceptable salt of the pyridine derivative or the prodrug, or a solvate of the pyridine derivative, the prodrug or the pharmaceutically acceptable salt, which is useful for treatment or prophylaxis of diseases associated with urat1 such as gout, hyperuricemia, hypertension, kidney diseases such as interstitial nephritis, diabetes, arteriosclerosis and lesch-nyhan syndrome.. .
Teijin Pharma Limited

Exendin-4 analogue pegylated with polyethylene glycol or derivative thereof, preparation method thereof, and pharmaceutical composition for preventing or treating diabetes, containing same as active ingredient

The present disclosure relates to an exendin-4 analogue pegylated with polyethylene glycol or a derivative thereof, a preparation method, and a pharmaceutical composition for prevention or treatment of diabetes containing the same as an active ingredient. According to the present invention, the yield of an exendin-4 analogue can be increased via the selective pegylation by using exendin-4 in which a cysteine is introduced into #40 site of the c-terminal, and treatment effect of medications can be increased, so that the exendin-analogue can be usefully applied as a composition for prevention or treatment of diseases caused by insulin hypersecretion..
Theraly Pharmaceuticals Inc.

Bacteroides cect 7771 and the use thereof in the prevention and treatment of excess weight, obesity and metabolic and immunological alterations

The invention relates to a strain of bacteroides uniformes with registration number cect 7771, and to the cellular constituents, metabolites and/or secreted molecules thereof. The invention also relates to a composition (nutritional or pharmaceutical) comprising at least one of the previous products.
Consejo Superior De Investigaciones Cientificas

Transgenic pig islets and uses thereof for treating diabetes

The present invention relates to an isolated transgenic pig beta cell wherein the pkc and the pka pathway are constitutively activated; to a transgenic pig islet comprising said transgenic pig beta cell; and to a transgenic pig comprising said transgenic pig beta cell or said transgenic pig islet. Another object of the invention is a device comprising a transgenic pig beta cell or a transgenic pig islet of the invention.
UniversitÉ Catholique De Louvain

Methods for treating insulin resistance and for sensitizing patients to glp1 agonist therapy

Methods for treatment of insulin resistance and type ii diabetes by administration of inhibitors of the pki pathway are provided. In some aspects, inhibitors of the pki pathway, such as inhibitors of pikb, hif1 and/or mtor, can be used to treat subject having insulin resistance who are refractory to glp1 agonist therapy..
Research Development Foundation

Combination therapy with sglt-2 inhibitors and their pharmaceutical compositions

The present invention is directed to a pharmaceutical composition comprised of one or more sglt-2 inhibitor compound(s) in combination with one or more therapeutic agents which is suitable for the treatment of metabolic disorders including type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, hyperglycemia, postprandial hyperglycemia, overweight, obesity, including class i obesity, class ii obesity, class iii obesity, visceral obesity and abdominal obesity, and metabolic syndrome.. .
Boehringer Ingelheim International Gmbh

Solid oral formulation of fenretinide

Amorphous solid dispersions suitable for oral delivery comprising fenretinide or an analog thereof and at least one matrix polymer, and processes for making the dispersions, are disclosed. Also disclosed are solid oral formulations comprising the amorphous solid dispersions, as well as uses thereof for the prevention and/or treatment of diseases or conditions treatable by fenretinide, including but not limited to cancers, conditions associated with a lipid imbalance, cystic fibrosis, osteoporosis, conditions associated with inflammation or opportunistic infections, and other diseases such as diabetes, obesity, dry-form age-related macular degeneration..
Laurent Pharmaceuticals

Pharmaceutical composition comprising rimeporide for treating diseases associated with insulin resistance and beta-cell dysfunction

The invention relates to a pharmaceutical composition comprising as active ingredient an effective amount of 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the prophylaxis and therapy of type ii diabetes mellitus, the metabolic syndrome, diabetic nephropathy and/or neuropathy. Another object of the invention concerns the use of 2-methyl-4,5-di-(methylsulfonyl)-benzoyl-guanidine, or derivatives thereof, for the enhancement of insulin sensitivity and the preservation or increase of β-cell compensation..
Merck Patent Gmbh

Composition and management of diabetes or pre-diabetes

Wherein the drink exhibits shear banding when subject to the shear banding test herein described.. .

System for screening and diagnosis of diabetes

This invention relates to the means for detection of molecular and chemical matter utilizing multiple techniques covering electronics, optics, and imaging techniques. More particularly, this invention is related to detecting levels of certain molecules inside the body through non-invasive contact or non-contact with the body.
Banpil Photonics, Inc.

Human antigen binding proteins that bind to a complex comprising beta-klotho and an fgf receptor

The present invention provides compositions and methods relating to or derived from antigen binding proteins capable of inducing b-klotho, and or fgf21-like mediated signaling. In embodiments, the antigen binding proteins specifically bind to a complex comprising β-klotho and at least one of (i) fgfr1c, (ii) fgfr2c and (iii) fgfr3c.
Amgen Inc.

Oxyntomodulin analogue

Provided is an oxyntomodulin analogue. The analogue comprises gcgr and glp-1r dual agonist activity, improved enzymolysis stability and biological activity, and no adverse reactions.

N-hydroxy bicyclic hydantoin carbamates as tools for indetification of serine hydrolase targets

Provided herein are n-hydroxy bicyclic hydantoin carbamates and pharmaceutical compositions comprising said compounds. The subject compounds and compositions are useful as modulators of serine hydrolases.
The Scripps Research Institute

Systemic delivery of virus vectors encoding urocortin-2 and related genes to treat diabetes-related cardiac dysfunctions and congestive heart failure

In alternative embodiments, provided are methods for treating, ameliorating or protecting (preventing) congestive heart failure (chf) or a diabetes-related cardiac dysfunction, comprising: providing a urocortin 2-encoding and/or a urocortin 3-encoding nucleic acid, transcript or message, or gene, operatively linked to a transcriptional regulatory sequence, optionally contained in an expression vehicle or a vector such as an adeno-associated virus (aav), e.g., an aav8 serotype; and administering to an individual or a patient in need thereof, such as a type 2 diabetic (t2dm), e.g., by iv administration, thereby treating, ameliorating or protecting against (preventing) the t2dm and/or the diabetes-related cardiac dysfunction in the individual or patient.. .
The Regents Of The University Of California

Agent for preventing or ameliorating diabetes

An object of the present invention is to find a component that is safe and is capable of effectively exerting various effects such as prevention or amelioration of diabetes, prevention or amelioration of metabolic syndrome, amelioration of insulin resistance, inhibition of an increase in a postprandial blood sugar level, and inhibition of α-glucosidase activity. The present invention provides agents for preventing or ameliorating diabetes or the like, the agents including a component of a hybrid plant of camellia sinensis and camellia taliensis as an active ingredient.
Kyushu University National University Corporation

Cannabinoid receptor antagonists/inverse agonists useful for treating metabolic disorders, including obesity and diabetes

The present invention provides novel, diastereomeric pyrazolines that are useful as cannabinoid receptor blockers and pharmaceutical compositions thereof and methods of using the same for treating obesity, diabetes, inflammatory disorders, cardiometabolic disorders, hepatic disorders, and/or cancers.. .
Jenrin Discovery

Modulators of gtpases and their use

The present invention relates to molecules which function as modulators (i.e., inhibitors and agonists) of the ras-homologous (rho) family of small gtpases (e.g. Rac, cdc42 and rho gtpases) and their use to treat diseases, including cancers (including solid tumors-medulloblastoma, ovarian, breast, head and neck, testicular, prostate among others and hematologic malignancies-b cell lymphoma, where these gtpases are overexpressed or hyperactivated), sporadic and genetic diseases where activation of rho gtpases plays a pivotal role (menkes disease, rheumatoid arthritis, atherosclerosis, diabetes (type i), huntington's disease and alzheimer's disease) which are mediated through these proteins.
Stc.unm

Methods of obtaining islet cells

The present invention provides methods and materials relating to obtaining or expanding populations of islet cells, and uses of the islet cells obtained by these methods, for example in the treatment of diabetes. The invention uses transcription factors in a process of expansion and de-differention, followed by redifferentiation..
Lothian Health Board

Compositions comprising cyclocarya paliurus extract and preparation method and uses thereof

Compositions and preparation method thereof, said compositions comprise herb extract from a mixture comprising cyclocarya paliurus leaf and one or two herbs selected from the group consisting of puerariae lobatae radix and polygonati odorati rhizoma, said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia.. .
Infinitus (china) Company Ltd

Tea composition comprising cyclocarya paliurus and preparation method and uses thereof

Compositions and preparation method thereof, said compositions comprise cyclocarya paliurus leaf and one or more herbs selected from the group consisting of green tea, mori folium, siraitiae fructus, broadleaf holly leaf and polygonati odorati rhizoma, and their preparation method. Said compositions can treat diabetes, hyperglycemia, hypertension and/or hyperlipidemia..
Infinitus (china) Company Ltd

Novel combination of naturally occurring compounds to assist with suspected mycobacterial infections related to autoimmune conditions

The novel aspect of this invention is that it is a unique formulation of naturally occurring compounds with a unique intention to assist the concerns associated with autoimmune conditions, mainly inflammatory bowel disease (collectively crohn's, ulcerative colitis, irritable bowel syndrome), type 1 diabetes, multiple sclerosis, psoriasis and the suspected infection of the pathogen mycobacterium avium sub-species paratuberculosis (map). Furthermore, its intent is to address the lack of treatment options available for those with aforementioned autoimmune conditions.

Apoptosis signal-regulating kinase inhibitors

Wherein variables are as defined above. The compounds have apoptosis signal-regulating kinase (“ask1”) inhibitory activity, and are thus useful in the treatment of ask1-mediated conditions, including autoimmune disorders, inflammatory diseases, cardiovascular diseases, diabetes, diabetic nephropathy, cardio-renal diseases, including kidney disease, fibrotic diseases, respiratory diseases, copd, idiopathic pulmonary fibrosis, acute lung injury, acute and chronic liver diseases, and neurodegenerative diseases..

Antidiabetic medications

Methods of using antidiabetic medications which are suitable in the treatment or prevention of one or more conditions selected from type 1 diabetes mellitus, type 2 diabetes mellitus, impaired glucose tolerance, and hyperglycemia, among others.. .
Boehringer Ingelheim International Gmbh

Methods and devices for the diagnosis and treatment of diabetes

Methods and devices for the diagnosis and treatment of diabetes are disclosed in which an analyte concentration within a peritoneal fluid of a human subject may be determined by implanting an analyte sensor apparatus in the subject where the apparatus may comprise a housing and a flexible sensing catheter which has a lumen with a plurality of apertures and an exterior surface with an analyte sensor affixed thereto. The catheter may comprise a proximal end attached to the housing and the remaining end may be positioned freely within the peritoneal space to contact peritoneal fluid where an analyte concentration in the peritoneal fluid may be sensed.
Theranova, Llc

In vitro process for the quantification of carboxymethyl and carboxyethyl level of albumin in a sample

An in vitro method for the identification and quantification of glycated human serum albumin to assess the extent of diabetic complications in diseased individuals. Further, a diagnostic kit for identifying the extent of diabetes in a diseased individual by estimating glycated serum albumin levels in such individuals..
Council Of Scientific & Industrial Research

Esculentin-2cha peptide and analogues thereof

The present invention relates to an esculentin-2cha peptide and analogues thereof, and the use each thereof in the treatment of diabetes, for example type 2 diabetes; insulin resistance; obesity, and/or hypercholesterolemia. Also disclosed is a pharmaceutical composition comprising peptides and analogues according to the present invention; use of peptides and analogues according to the present invention for the manufacture of a medicament for the treatment of diabetes, insulin resistance, obesity, and/or hypercholesterolemia; and methods of treating diabetes, insulin resistance, obesity, and/or hypercholesterolemia..
University Of Ulster

Antidiabetic substituted heteroaryl compounds

The present invention relates to a compound represented by formula (i): and pharmaceutically acceptable salts thereof. The compounds of formula i are agonists of g-protein coupled receptor 40 (gpr40) and may be useful in the treatment, prevention and suppression of diseases mediated by the g-protein-coupled receptor 40.
Merck Sharp & Dohme Corp.

O-glcnac transferase (ogt) inhibitors and uses thereof

The present invention provides inhibitors of o-glcnac transferase. Typically, the inhibitors are quinolinone-6-sulfonamides.
The United States Of America, As Represented By The Secretary, Department Of Health And Human

Process for the preparation of dapagliflozin

Dapagliflozin compounds and process for dapagliflozin preparation are described. Pharmaceutical compositions comprising dapagliflozin or solvates of dapagliflozin, for the treatment of diabetes are also described..
Cadila Healthcare Limited

Compositions and methods for treating diabetes and liver diseases

Compounds, compositions, and methods are described herein for treating diabetes, fatty liver diseases, fibrotic diseases, such as liver and pulmonary fibrosis, and hepatocellular carcinoma.. .
Cempra Pharmaceuticals, Inc.

Heteroaromatic compounds and their use as dopamine d1 ligands

And pharmaceutically acceptable salts thereof and n-oxides thereof; processes for the preparation of; intermediates used in the preparation of; and compositions containing such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) and the uses of such compounds (n-oxides thereof or or pharmaceutically acceptable salts of the compound or the n-oxides) for the treatment of d1-mediated (or d1-associated) disorders including cognitive and motivational impairments and negative symptoms associated with illnesses such as schizophrenia, depression, bipolar disorder, parkinson's disease, mild cognitive impairment (mci), alzheimer's disease, lupus, huntington's disease, parkinson's, dyskinesia, adhd, post-traumatic stress disorder, autism spectrum disorder, treatment-resistant depression, major depressive disorder (mdd), drug dependence, tourette's syndrome, tardive dyskinesias as well as impairments associated with age, chronic stress, sleep deprivation, combat, chronic fatigue; endocrine or metabolic diseases such as hyperglycemia, dislipidemia, diabetes, obesity, and sepsis; and cardiovascular disorder such as hypertension. The present invention further provides a d1 agonist with reduced d1r desensitization, a d1 agonist with a reduced β-arrestin recruitment activity relative to dopamine, a d1 agonist interacting significantly with the ser188 but not significantly with the ser202 of a d1r when binding to the d1r, a d1 agonist interacting less strongly the asp103 and interacting less strongly with the ser198 of a d1r when binding to the d1r, and their uses..

Mutation for type i diabetes mellitus and animal model

The invention relates to a mutation in the dock8 encoding gene that is causative for type 1 diabetes mellitus at least in the rat (rattus norvegicus) or mouse, the rat or mouse preferably having an mhc predisposing towards type 1 diabetes mellitus and/or a mutation in the von willebrand factor vwa2. Embodiments of the invention comprise a process for generating a non-human mammal by genetic manipulation to contain at least heterozygously, preferably homozygously, the mutation causative for type 1 diabetes mellitus, preferably in combination with an mhc predisposing for type 1 diabetes mellitus and/or with a mutation in the von willebrand factor vwa2..
Medizinische Hochschule Hannover

Means and methods for determining risk of type-1 diabetes by serum protein biomarkers

The present invention relates to methods for predicting a risk of a subject for type 1 diabetes (t1d) on the basis of expression levels of protein markers in a sample obtained from the subject. The present invention also relates to in vitro kits for use in said methods..
Turun Yliopisto

High load enzyme immobilization by crosslinking

Methods of cross-linking polypeptide molecules are provided, where such methods include combining a cross-linking agent and polypeptide molecules in a solution under conditions suitable for a cross-linking reaction to occur. Also provided are preparations of cross-linked polypeptide molecules, where the polypeptide molecules are cross-linked by essentially unbranched cross-linking groups of at least 40 contiguous atoms.
Roche Diabetes Care, Inc.

Novel compound, pharmaceutically acceptable salt or optical isomer thereof, preparing the same, and pharmaceutical composition for prevention or treatment of viral diseases containing same as active ingredient

The present invention relates to a novel compound, to a pharmaceutically acceptable salt or optical isomer thereof, to a method for preparing same, and to a pharmaceutical composition for the prevention or treatment of viral diseases containing same as an active ingredient. The novel compound according to the present invention not only has low cytotoxicity but also has excellent antiviral activity against picornavirus such as coxsackievirus, enterovirus, echovirus, poliovirus and rhinovirus, and thus can be effectively used as a pharmaceutical composition for the prevention or treatment of viral diseases such as infantile paralysis, acute hemorrhagic conjunctivitis, viral meningitis, hand-foot-and-mouth disease, vesicular disease, hepatitis a, myitis, myocarditis, pancreatitis, diabetes, epidemic myalgia, encephalitis, cold, herpangina, foot-and-mouth disease, asthma, chronic obstructive pulmonary disease, pneumonia, sinus infection, or otitis media..
Katholieke Universiteit Leuven K.u. Leuven R & D

Co-crystal of dapagliflozin with citric acid

The present invention relates to a dapagliflozin-citric acid co-crystal, processes for its preparation, and its use for the treatment of type 2 diabetes mellitus. A dapagliflozin citric acid co-crystal.
Sun Pharmaceutical Industries Limited

Method for producing 4,4,7-trifluoro-1,2,3,4-tatrahydro-5h-1-benzazepine compound and intermediate used in the method

The present invention provides a method for producing a 4,4,7-trifluoro-1,2,3,4-tetrahydro-5h-1-benzazepine compound which has an superior agonistic activity to an arginine vasopressin v2 receptor and is useful as an active ingredient for a pharmaceutical composition for preventing and/or treating urinary frequency, urinary incontinence, enuresis, central diabetes insipidus, nocturia, nocturnal enuresis, or the like; and useful intermediates for use in the methods. The production method of the present invention is suitable for the industrial production of a medicament, because of a smaller number of steps, a higher yield, and a lower cost, as compared with the methods in the related art..
Tacurion

Methods for inducing insulin production and uses thereof

The invention relates to methods of inducing insulin production in delta-cells and/or converting delta-cells into insulin producing cells, as well as methods of preventing and/or treating diabetes and agents and compositions useful in said methods.. .
Universite De Geneve

Early prediction markers of diabetic nephropathy

The present invention concerns a method for the in vitro detection of an increased risk of diabetic nephropathy in a subject suffering from diabetes and being normoalbuminuric. Another aspect of the invention pertains to a method for the in vitro identification of a marker for prediction of diabetic nephropathy.
Chu Montpellier

Inhibitors of the farnesoid x receptor and uses in medicine

Disclosed are inhibitors of the farnesoid x receptor, for example of formula (i), wherein r1, r2, r4, x, y, z, m, and n are as defined herein, which are useful in treating or preventing obesity, type 2 diabetes/insulin resistance and non-alcoholic fatty liver disease in a mammal in need thereof. Also disclosed is a composition comprising a pharmaceutically suitable carrier and at least one compound of the invention, a method of method of inhibiting a farnesoid x receptor in a mammal, and a method of treating or preventing obesity in a mammal..
The Penn State Research Foundation

Crystalline solvate forms of a pharmaceutical

The invention provides and describes solid state 17α-ethynyl-androst-5-ene-3β,7β,17β-triol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-androst-5-ene-3β,7β,17β-triol include form i anhydrate and form iv and form v solvates.
Neurmedix, Inc.

Pyrazine derivatives

Provided is a novel pyrazine derivative represented by the following formula (i) or a pharmaceutically acceptable salt thereof, or a solvate thereof which is useful for treating or preventing diseases in which urat1 is involved, including gout, hyperuricemia, hypertension, renal diseases such as interstitial nephritis and the like, diabetes, arteriosclerosis, lesch-nyhan syndrome, and the like.. .
Teijin Pharma Limited

Compositions and methods for treating obesity and related disorders by characterizing and restoring mammalian bacterial microbiota

The present invention relates to characterizing changes in mammalian intestinal microbiota associated with associated with high-fat and low-fat diets and with diets containing hydroxypropylmethylcellulose (hpmc) and related methods for diagnosing, preventing and treating obesity and related conditions such as metabolic syndrome and diabetes mellitus. Therapeutic methods of the invention involve the use of probiotics, and/or prebiotics, and/or narrow spectrum antibiotics/anti-bacterial agents that are capable of restoring healthy mammalian bacterial intestinal microbiota..
New York University

Systems and methods of diabetes management

Presented herein are one or more software applications to help a user manager their diabetes. Embodiments and descriptions of the various applications are provided below in conjunction with an analyte measurement device..

Glp-1 derivatives

The invention relates to a derivative of a glp-1 peptide, which peptide has two lys residues, namely a first and a second lys residue, and a maximum of eight amino acid changes as compared to glp-1(7-37) (seq id no: 3), which derivative comprises two protracting moieties attached to the epsilon amino group of said first and second lys residue, respectively, via a linker, wherein the protracting moiety is selected from chem. 15: hooc—(ch2))x—co—*, and chem.

Canagliflozin monohydrate and its crystalline forms, preparation methods and uses thereof

The present invention relates to canagliflozin monohydrate and its crystalline forms. Compared to the prior art, canagliflozin monohydrate and its crystalline forms have higher stability in water or aqueous system, is more suitable for wet granulation processes or suspension preparations and have good storage stability.

Crystalline forms and processes for the preparation of cannabinoid receptor modulators

The present invention relates to crystalline forms of (1as,5as)-2-(4-oxy-pyrazin-2-yl)-1a,2,5,5a-tetrahydro-1h-2,3-diaza-cyclopropa[a]pentalene-4-carboxylic acid ((s)-1-hydroxymethyl-2,2-dimethyl-propyl)-amide (compound 1) and pharmaceutical compositions thereof that modulate the activity of the cannabinoid cb2 receptor and are therefore useful in the treatment of cb2 receptor-mediated disorders, for example, osteoarthritis; pain; hyperalgesia; allodynia; inflammatory hyperalgesia; neuropathic hyperalgesia; acute nociception; osteoporosis; multiple sclerosis-associated spasticity; autoimmune disorders; allergic reactions; cns inflammation for example; atherosclerosis; undesired immune cell activity, and inflammation associated with a disorder selected from: osteoarthritis, anaphylaxis, behcet's disease, graft rejection, vasculitis, gout, spondylitis, viral disease, bacterial disease, lupus, inflammatory bowel disease, autoimmune hepatitis, and type 1 diabetes mellitus; age-related macular degeneration; cough; leukemia; lymphoma; cns tumors; prostate cancer; alzheimer's disease; stroke-induced damage; dementia; amyotrophic lateral sclerosis; and parkinson's disease.. .

Velocity-weighting model predictive control of an artificial pancreas for type 1 diabetes applications

Methods, devices, algorithms, and systems controlling insulin delivery employ velocity-weighting. Predicted glucose outcomes are penalized with a cost modulated by a factor that is a function of the glucose velocity, wherein glucose outcomes are penalized increasingly less for increasingly negative glucose velocities, when glucose level is high, and/or wherein a hyperglycemic glucose value that is already converging to the euglycemic zone results in less corrective action by the controller than were the hyperglycemic state steady..

Rituximab induction therapy followed by glatiramer acetate therapy

The present invention provides a method of treating a subject afflicted with a form of multiple sclerosis or presenting a clinically isolated syndrome comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject, wherein the amounts are effective to treat the subject. The present invention also provides a method of treating a subject afflicted with an immune disease, comprising periodic administration of an amount of rituximab at least twice to the subject followed by periodic administration of an amount of glatiramer acetate to the subject wherein the amounts are effective to treat the subject, and wherein the immune disease is an autoimmune disease, an arthritic condition, a demyelinating disease, an inflammatory disease, multiple sclerosis, relapsing-remitting multiple sclerosis, diabetes mellitus, psoriasis, rheumatoid arthritis, inflammatory bowel disease, crohn's disease, or systemic lupus erythematosus..

Composition for treating diabetes comprising long-acting insulin analogue conjugate and long-acting insulinotropic peptide conjugate

The present invention relates to a composition for the prevention or treatment of diabetes including a long-acting insulin conjugate and a long-acting insulinotropic peptide conjugate, and a method for treating diabetes. More specifically, combination administration of the long-acting analogue conjugate and the long-acting insulinotropic peptide conjugate inhibits weight gain due to administration of insulin, and vomiting and nausea due to administration of the insulinotropic peptide, and also reduces the required doses of insulin, thereby remarkably improving drug compliance.

Pharmaceutical combination for use in glycemic control in diabetes type 2 patients

The present invention refers to a pharmaceutical combination for use in glycemic control in diabetes type 2 patients.. .

Calcitonin mimetics for treating diseases and disorders

Calcitonin mimetic peptides having an amino acid sequence in accordance with seq id no:8 or seq id no:53, each of which may be carboxylated at its n-terminal or otherwise modified to reduce the positive charge of the first amino acid and independently of that may be amidated at its c-terminal, and in each of which the 1 and 7 position cysteine residues may together be replaced by α-aminosuberic acid (asu) are useful as medicaments for treating diabetes (type i and/or type ii), excess bodyweight, excessive food consumption, metabolic syndrome, rheumatoid arthritis, non-alcoholic fatty liver disease, osteoporosis, or osteoarthritis, poorly regulated blood glucose levels, poorly regulated response to glucose tolerance tests, or poorly regulated of food intake.. .

Modulation of cellular stress

Disclosed are compositions and methods for modulating oxidative and/or endoplasmic reticulum (oer) stress. More particularly, the present invention discloses compositions and methods that target oer stress inhibitors to pancreatic cells for treating diseases associated with oxidative and/or oer stress, including metabolic disorders such as diabetes..

Aav mediated exendin-4 gene transfer to salivary glands to protect subjects from diabetes or obesity

The invention relates to a gene transfer-based method to protect a subject from diabetes or obesity. The method comprises administering to a salivary gland of the subject an aav virion comprising an aav vector that encodes an exendin-4 protein.

Calcium folate (cafolate) and therapeutic methods based thereon

Disclosed herein are methods for the treatment of cancer and inflammatory-based diseases and disorders, such as hepatitis b virus infection, tuberculosis and type 2 diabetes based upon the administration of cafolate. In one embodiment is a method of treating cancer comprising administration of cafolate.

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Provided are compositions comprising compounds or precursors to compounds which may be used for a variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases. The compounds relate generally to urolithins and precursors thereof, including but not limited to ellagitannins and urolithin a.

Compositions and methods for improving mitochondrial function and treating neurodegenerative diseases and cognitive disorders

Provided are compositions comprising compounds or precursors to compounds which may be used for a. Variety of therapeutic applications including, for example, treating and/or preventing a disease or disorder related to reduced or inadequate mitochondrial activity, including aging or stress, diabetes, obesity, and neurodegenerative diseases.

Effect of lipophilic nutrients on diabetic eye diseases

Compositions containing molecular dispersions of lipophilic nutrients and methods thereof are provided for delaying the development and maturation of eye related complications of diabetes by administering a composition containing lipophilic nutrients. More particularly, methods relate to delaying the development and maturation of eye related complications of diabetes by administering a composition containing lutein and its isomers, lutein ester, zeaxanthin isomers, turmeric extract, curcumin or curcuminoids, derived from plant extract/oleoresin containing xanthophylls/xanthophylls esters which are safe for human consumption and are particularly useful as dietary supplements for nutrition and health promoting benefits..

Device and method to detect diabetes in a person using pulse palpation signal

A device and method is provided for the detection of diabetes in a person using pulse palpation signals. The pulse palpation signal is captured from the radial artery of the person using a photo-plethysmograph (ppg) sensor.

Apoiii and the treatment and diagnosis of diabetes

The present invention provides methods of identifying candidate compounds for the treatment of type i diabetes comprising contacting pancreatic β cells with an amount of apolipoprotein ciii (“apociii”) effective to increase intracellular calcium concentration, in the presence of one or more test compounds, and identifying those test compounds that inhibit an apociii-induced increase in intracellular calcium concentration in the pancreatic β cells. The present invention also provides methods for treating patients with type i diabetes comprising administering to the patient an amount effective of an inhibitor of apociii to reduce apociii-induced increase in intracellular calcium concentration in pancreatic β cells..
Biocrine Ab

Organic compositions to treat apoc3-related diseases

The present disclosure relates to compositions and methods for treating apoc3-related diseases such as: hypertriglyceridemia (e.g., type v hypertriglyceridemia), abnormal lipid metabolism, abnormal cholesterol metabolism, atherosclerosis, hyperlipidemia, diabetes, including type 2 diabetes, obesity, cardiovascular disease, and coronary artery disease, among other disorders relating to abnormal metabolism or otherwise, using a therapeutically effective amount of a rnai agent to apoc3.. .
Arrowhead Pharmaceuticals, Inc.

Compositions and methods for treating diabetes

Compositions containing an fkbp 11 peptide (i.e., fkbp11 polypeptide, a variant or a fragment thereof), a fusion protein containing an fkbp11 peptide, or a nucleic acid encoding an fkbp 11 peptide are disclosed. Also disclosed are methods of reducing blood glucose levels, improving glucose tolerance, decreasing hepatic gluconeogenic activity and/or improving insulin sensitivity in a subject, by administering a composition containing an fkbp 11 peptide or a fusion protein containing an fkbp11 peptide.
The Children's Medical Center Corporation

Vaccines and monoclonal antibodies targeting truncated variants of osteopontin and uses thereof

The present invention provides monoclonal antibodies specific for one or more truncated variants of human osteopontin and vaccines comprising at least one isolated osteopontin peptide, as well methods for manufacturing said antibodies and vaccines. Furthermore, a diagnostic method making use of said antibodies is provided.
Affiris Ag

Treatment of chronic kidney disease and other renal dysfunction using a gdf15 modulator

The invention provides methods and compositions for treating a subject having a renal-related disorder, such as chronic kidney disease (ckd), end stage renal failure, diabetes, insulin resistance, kidney hypertrophy, kidney hypotrophy, polycystic kidney disease, proteinuria, hyperglycemia, hyperuricemia, gout, kidney stones, hypertension or hypertensive nephropathy, dyslipidemia, anemia and/or reduced erythropoietin production, iron deficiency or hyperfiltration. The methods and compositions use or contain a composition that reduces or inhibits gdf15 activity..
Aveo Pharmaceuticals, Inc.

Long-acting single-chain insulin analogues

A single-chain insulin analogue containing a basic side chain at position a8 (arginine, histidine, lysine, or ornithine), a basic side chain at position b29 (arginine, histidine, lysine, or ornithine), and a foreshortened c-domain of length 6-11 residues is provided. Residues c1 and c2 of the c-domain have a net negative charge of −1 or −2; c3 is chosen from a group consisting of gly, ala, pro, or ser; and the remaining c-domain segment is successively derived from the c-domain of igf-ii (rrsr, srrsr, vsrrsr, rvsrrsr, or srvsrrsr; seq id no: 13).
Case Western Reserve University

Peptide yy (pyy) analogues

Analogues of peptide yy (pyy), which are useful in treating disorders such as diabetes and obesity and also for inducing cosmetic weight loss, related compositions, formulations, uses and methods.. .
Imperial Innovations Limited

Insulin-containing prolonged-action preparation

The invention relates to the field of biotechnology and medicine, and specifically to insulin-containing injectable formulations used, in particular, for treating diabetes mellitus. The present formulation comprises insulin and a pharmacologically acceptable polymer having a hydrodynamic diameter of more than 4.5+/−0.5 nanometers.
Obschestvo S Ogranchennoj Otvetctvennostu "biosabtek"

Methods of treatment using a pentapeptide derived from the c-terminus of glucagon-like peptide 1 (glp-1)

Methods of treating obesity, metabolic syndrome, hepatic and non-hepatic steatosis, and diabetes using a pentapeptide, lvkgramide, derived from the c-terminus of glucagon-like peptide 1 (glp-1).. .
The General Hospital Corporation

Method of treatment of diabetes type 2 comprising add-on therapy to insulin glargine and metformin

To a subject in need thereof.. .

Anti-glycation methods and compositions

The present invention comprises compositions that provide anti-glycation activity comprising a mineral extract composition or a mogroside/mineral extract composition or a mogroside composition. Such compositions are useful for methods of preventing, treating and inhibiting the effects of glycation in the body.
Core Intellectual Properties Holdings, Llc

Pharmaceutical compositions of berberine with epa and dha, and methods thereof

The invention provides various novel compositions of berberine in combination with pharmacologically active epa and dha, and related methods of their use in treating various diseases or disorders. The pharmaceutical compositions of the invention are useful in treating and/or preventing various diseases or disorders, including metabolic diseases or disorders such as dyslipidemia, hyperglycemia, hypertriglyceridemia, hyperlipidemia, diabetic dyslipidemia, diabetic hyperlipidemia, dyslipidemia in statin-intolerance patients, diabetes, diabetic complications, hypercholesterolemia, or obesity.
Shenzhen Hightide Biopharmaceutical, Ltd.

Method for suppressing glucagon secretion of an sglt2 inhibitor

Methods are provided for avoiding an increase in glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor. Additionally, methods are provided for normalizing the glucagon secretion associated with the administration of a sodium glucose co-transporter 2 (sglt2) inhibitor via the co-administration of a dipeptidyl peptidase iv (dpp iv) inhibitor.
Astrazeneca Ab

Systems using fingerprint images as diagnostic detection systems for type 2 diabetes

Method and kits for determining a propensity to develop type 2 diabetes mellitus (t2dm) in an individual by measuring an asymmetry of a captured fingerprint from the individual are described.. .
Ohio University



Diabetes topics:
  • Immune Disorder
  • Autoimmune
  • Immune Disease
  • Immune Diseases
  • Autoimmune Disorder
  • Type 1 Diabetes
  • Autoimmune Disorders
  • Vascular Diseases
  • Antimicrobial
  • Cardiovascular
  • Inflammatory Disease
  • Antimicrobial Agent
  • Stem Cells
  • Human Embryonic Stem Cell
  • Embryonic Stem Cell


  • Follow us on Twitter
    twitter icon@FreshPatents

    ###

    This listing is a sample listing of patent applications related to Diabetes for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for Diabetes with additional patents listed. Browse our RSS directory or Search for other possible listings.


    1.6951

    file did exist - 12204

    0 - 1 - 251